Literature DB >> 9010629

Metabolites of nicotine in rat brain after peripheral nicotine administration. Cotinine, nornicotine, and norcotinine.

P A Crooks1, M Li, L P Dwoskin.   

Abstract

The time course of nicotine metabolite appearance in brain from 5 min-18 hr after subcutaneous administration of S-(-)-[3H-N-methyl]nicotine was determined. Results demonstrated that metabolite appearance in brain was greatest at 4 hr postadministration, whereas levels of nicotine were greatly diminished at this time point. For determination of N-demethylated metabolites, (+/-)-[2'-14C]nicotine was administered subcutaneously to rats, and the presence of nicotine and nicotine metabolites in brain supernatant was determined 4 hr postadministration. Using high-performance liquid radiochromatographic analysis, nicotine and three nicotine metabolites (cotinine, nornicotine, and norcotinine) were identified in brain, together with a fourth minor, unidentified metabolite. After subcutaneous administration of S-(-)-[G-3H]cotinine, significant amounts of cotinine were found in brain over an 18-hr postadministration period; however, no cotinine metabolites were detected. Therefore, cotinine is able to pass the blood-brain barrier and access the central nervous system, but is not biotransformed in brain. Thus, this is the first report of norcotinine as a central nervous system nicotine metabolite. Data indicate that norcotinine detected in brain after peripheral nicotine administration most likely originates from 5'-C-oxidation of brain nornicotine, rather than from N-demethylation of cotinine, as occurs peripherally. Because peripheral biotransformation of nicotine to nornicotine is a minor pathway, the relatively high levels of nornicotine found in brain after peripheral nicotine administration suggest that nornicotine is formed via oxidative N-demethylation of nicotine locally in brain. Nornicotine is pharmacologically active; thus, its presence in brain after peripheral nicotine administration indicates that nornicotine may contribute to the neuropharmacological effects of nicotine and tobacco use.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010629

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  23 in total

1.  A previously undescribed chemical link between smoking and metabolic disease.

Authors:  Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-28       Impact factor: 11.205

Review 2.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

3.  Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Authors:  Paula L Vieira-Brock; Eleanor I Miller; Shannon M Nielsen; Annette E Fleckenstein; Diana G Wilkins
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-09-18       Impact factor: 3.205

4.  A general procedure for the enantioselective synthesis of the minor tobacco alkaloids nornicotine, anabasine, and anatabine.

Authors:  Joshua T Ayers; Rui Xu; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2005-10-31       Impact factor: 4.009

Review 5.  Nicotine reduction revisited: science and future directions.

Authors:  Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller
Journal:  Tob Control       Date:  2010-10       Impact factor: 7.552

Review 6.  Behavioral mechanisms underlying nicotine reinforcement.

Authors:  Laura E Rupprecht; Tracy T Smith; Rachel L Schassburger; Deanne M Buffalari; Alan F Sved; Eric C Donny
Journal:  Curr Top Behav Neurosci       Date:  2015

7.  The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats.

Authors:  Alvin V Terry; Jerry J Buccafusco; R Foster Schade; Leah Vandenhuerk; Patrick M Callahan; Wayne D Beck; Elizabeth J Hutchings; James M Chapman; Pei Li; Michael G Bartlett
Journal:  Biochem Pharmacol       Date:  2012-01-08       Impact factor: 5.858

8.  Altered retinoid homeostasis catalyzed by a nicotine metabolite: implications in macular degeneration and normal development.

Authors:  Andrew P Brogan; Tobin J Dickerson; Grant E Boldt; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-13       Impact factor: 11.205

9.  Common effects of fat, ethanol, and nicotine on enkephalin in discrete areas of the brain.

Authors:  G-Q Chang; O Karatayev; J R Barson; S C Liang; S F Leibowitz
Journal:  Neuroscience       Date:  2014-07-30       Impact factor: 3.590

10.  Time-course of extracellular nicotine and cotinine levels in rat brain following administration of nicotine: effects of route and ethanol coadministration.

Authors:  Simon N Katner; Jamie E Toalston; Michael P Smoker; Zachary A Rodd; William J McBride; Eric A Engleman
Journal:  Psychopharmacology (Berl)       Date:  2014-07-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.